C12N 2310/35
Nature of the modification
C12N2310/35 (Nature of the modification) appears on 3,371 US grants and 6,348 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,371
- Published applications
- 6,348
- Assignees
- 1,458
- Inventors
- 7,667
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 4 | 0 |
| 1994 | 4 | 0 |
| 1995 | 6 | 0 |
| 1996 | 27 | 0 |
| 1997 | 50 | 0 |
| 1998 | 45 | 0 |
| 1999 | 44 | 0 |
| 2000 | 37 | 0 |
| 2001 | 35 | 8 |
| 2002 | 42 | 26 |
| 2003 | 20 | 75 |
| 2004 | 14 | 70 |
| 2005 | 13 | 76 |
| 2006 | 14 | 97 |
| 2007 | 10 | 70 |
| 2008 | 14 | 65 |
| 2009 | 29 | 131 |
| 2010 | 48 | 123 |
| 2011 | 74 | 150 |
| 2012 | 92 | 160 |
| 2013 | 104 | 163 |
| 2014 | 106 | 193 |
| 2015 | 174 | 285 |
| 2016 | 175 | 345 |
| 2017 | 207 | 294 |
| 2018 | 210 | 382 |
| 2019 | 245 | 366 |
| 2020 | 242 | 387 |
| 2021 | 247 | 449 |
| 2022 | 228 | 458 |
| 2023 | 208 | 508 |
| 2024 | 215 | 577 |
| 2025 | 227 | 540 |
| 2026 | 161 | 350 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- CAS12B enzymes and systems6 Oct 2026US 12,753,406 B2Massachusetts Institute of Technology
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Riboswitch modulated gene therapy for retinal diseases29 Sep 2026US 12,747,441 B2The Medical College of Wisconsin, Inc.
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
- Nucleic acid-peptide-nucleic acid conjugate molecules and methods of making the same1 Oct 2026US 2026/0295069 A1Arizona Board of Regents on behalf of Arizona State University
Most cited
By later US patents
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved663US 5,403,711 AUniversity of Iowa Research Foundation · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997